title: Molecular profiling of non-small cell lung cancer: of what value in clinical practice?
abstract: Future improvements in lung cancer survival are likely to come from delineating its putative oncogenic pathways. The development of microarray technology to perform thousands of simultaneous genetic experiments and the linking of this to clinical information is an imperative for refining our current treatments and developing new ones. This paper reviews the state of this research, describes a typical microarray experiment and the implications for diagnosis and treatment of non-small cell lung cancer.
authors.affiliation: Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia.
authors.forename: Genni M
authors.initials: GM
authors.lastname: Newnham
authors.forename: David M
authors.initials: DM
authors.lastname: Thomas
authors.forename: Sue Anne
authors.initials: SA
authors.lastname: McLachlan
authors.forename: Gavin
authors.initials: G
authors.lastname: Wright
authors.forename: Matthew
authors.initials: M
authors.lastname: Conron
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D016172:DNA Fingerprinting; D015195:Drug Design; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor